about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyIntegrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1Twenty years of anti-HER2 therapy-associated cardiotoxicityThe role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitorsCardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Breast cancer therapy and cardiovascular risk: focus on trastuzumabCombined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors.Drug-induced mitochondrial dysfunction and cardiotoxicity.Risk factors for anthracycline-associated cardiotoxicity.Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.Drug-induced oxidative stress and toxicity.The role of Notch pathway in cardiovascular diseases.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Trastuzumab-associated cardiac events in the Persephone trial.Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress.Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.
P2860
Q21284978-A6D77469-F148-4D98-9F54-DA4C67DAFC43Q26771931-01D79A02-427D-455A-A147-2EE5EDF26F41Q28079391-2F672193-038C-4663-B236-838D52257BFCQ28081504-CD3F4BC3-2B87-4CC7-B4D1-2AFB281BDEE3Q33831903-990676AE-D7F2-43A1-BBCF-30797FA798F4Q33949465-5AC02739-0A8A-45C5-BF33-42B69AFF579AQ35427876-4338F546-D7F9-4948-93E8-C1A992801707Q35937896-DE4A5100-1412-48CF-9E4D-2AAAB661A267Q36339445-3B385F4A-F31D-4443-8C5A-53974C7695E6Q36921775-4362F220-0C29-462A-888C-70DBAAB0C9E0Q36963554-AA63B2E6-66E4-40E6-B70E-5A78ED832353Q37172361-0F7815E7-4D0D-44C3-B406-C1017AE0C845Q37205811-0C144542-0C31-47DB-81D5-D420B633972CQ37690877-CFA1DAA3-5694-4648-9527-7FE4208492DFQ38037517-BBD305A2-CD00-42D3-80A6-5E471A84743CQ38205776-3A81F25E-0FBF-44B3-A21E-741ED9C16A43Q38854876-186145A0-C8BC-4B10-A2FF-FA81D56A4241Q39163356-3D150B44-0E01-49C2-83F9-31038BE364FCQ42368225-47F960C4-4DD5-418D-AD2B-426C35C4486AQ45374763-18AB8DF9-F2E4-4D64-A374-7536D2200119Q49961375-3B4B88A5-CD43-4722-B865-39C5AC55294DQ51735129-EFC7A12F-2443-49F5-B79E-E820D90423ECQ55222160-A3875A0F-5C6E-4BE0-ADFD-0456A348EADB
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@ast
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@en
type
label
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@ast
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@en
prefLabel
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@ast
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@en
P2093
P2860
P1476
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'
@en
P2093
Davinder S Jassal
Pawan K Singal
P2860
P577
2011-01-01T00:00:00Z